Literature DB >> 18465337

Recurrence pattern and prognosis in low-risk breast cancer patients--data from the DBCG 89-A programme.

Peer Christiansen1, Nidal Al-Suliman, Karsten Bjerre, Susanne Møller.   

Abstract

The invasive disease free survival, the overall survival, and the relative risk of death compared to the Danish population as well as the risk of recurrence and new malignancies is reported for low-risk breast cancer patients of the DBCG 89-A programme. The study includes a comparison between those patients who, according to the present criteria, would be defined low-risk and those who would be defined high-risk (the retrospective lowhigh-risk group) and a comparison of treatment by mastectomy and BCS combined with radiation therapy. The DBCG 89-A programme scheduled 10 years of follow-up. Data was supplemented by record linkage to the Hospital Discharge Registry (date of event) and the Central Population Registry (date of death). The study population consisted of 8 850 patients. With 12 years of follow-up 3 811 events (43%) were recorded: loco-regional recurrence 8%, distant recurrence 11%, contralateral cancer 6%, secondary cancer 8%, and deaths 11%. The DBCG registry had an incomplete reporting of events in these low-risk patients, due to premature discontinuation of control. The incidence of recurrences was higher for the retrospective low --> high-risk group than for the low-risk group. The 10-year overall survival was 76%; lower in the retrospective low --> high-risk group (71%) than in the low-risk group (83%). The 5-year survival following local recurrence was 68% after mastectomy and 81% after BCS. The risk of mortality was higher than in the general population for all subgroups of patients. The relative risk of mortality expressed in terms of the standardized mortality ratio was 10.4 for young patients (26-39 years) and 1.2 for old patients aged 70-74 years and 1.3 for patients in the retrospective low-risk group and 1.9 for patients in the low --> high-risk group. The loco-regional treatment given did not cure all patients, in particular young patients and those of the retrospective low --> high-risk group.

Entities:  

Mesh:

Year:  2008        PMID: 18465337     DOI: 10.1080/02841860802056594

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  16 in total

1.  [Risk-adapted targeted intraoperative radiotherapy versus whole breast irradiation in breast cancer patients].

Authors:  Marc D Piroth
Journal:  Strahlenther Onkol       Date:  2014-08       Impact factor: 3.621

Review 2.  Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.

Authors:  Bernd Gerber; Mathias Freund; Toralf Reimer
Journal:  Dtsch Arztebl Int       Date:  2010-02-12       Impact factor: 5.594

3.  Opioids and breast cancer recurrence: A Danish population-based cohort study.

Authors:  Deirdre P Cronin-Fenton; Uffe Heide-Jørgensen; Thomas P Ahern; Timothy L Lash; Peer M Christiansen; Bent Ejlertsen; Per Sjøgren; Henrik Kehlet; Henrik T Sørensen
Journal:  Cancer       Date:  2015-07-24       Impact factor: 6.860

4.  Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.

Authors:  Jie Zhou; Shikun Qian; Hongsheng Li; Weixing He; Xiaojun Tan; Qiong Zhang; Guodong Han; Guiquan Chen; Rongcheng Luo
Journal:  Tumour Biol       Date:  2015-03-14

5.  Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.

Authors:  Cathrine F Hjorth; Anja S Nielsen; Henrik T Sørensen; Timothy L Lash; Per Damkier; Stephen Hamilton-Dutoit; Deirdre Cronin-Fenton
Journal:  Acta Oncol       Date:  2018-11-20       Impact factor: 4.089

Review 6.  Current Treatment of Isolated Locoregional Breast Cancer Recurrences.

Authors:  Wolfgang Harms; Andreas Geretschläger; Corinne Cescato; Martin Buess; Dieter Köberle; Branca Asadpour
Journal:  Breast Care (Basel)       Date:  2015-08-21       Impact factor: 2.860

7.  Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.

Authors:  Deirdre P Cronin-Fenton; Uffe Heide-Jørgensen; Thomas P Ahern; Timothy L Lash; Peer Christiansen; Bent Ejlertsen; Henrik T Sørensen
Journal:  Epidemiology       Date:  2016-07       Impact factor: 4.822

8.  Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.

Authors:  Cathrine F Hjorth; Per Damkier; Tore B Stage; Søren Feddersen; Stephen Hamilton-Dutoit; Mikael Rørth; Bent Ejlertsen; Timothy L Lash; Thomas P Ahern; Henrik T Sørensen; Deirdre Cronin-Fenton
Journal:  Breast Cancer Res Treat       Date:  2022-04-30       Impact factor: 4.624

9.  Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients.

Authors:  Daniella Klebaner; Stephen Hamilton-Dutoit; Thomas Ahern; Anatasha Crawford; Thomas Jakobsen; Deirdre P Cronin-Fenton; Per Damkier; Emiel Janssen; Anders Kjaersgaard; Anne Gulbech Ording; Håvard Søiland; Henrik Toft Sørensen; Timothy L Lash; Ylva Hellberg
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

10.  DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences.

Authors:  Wolfgang Harms; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; D Krug; M D Piroth; M-L Sautter-Bihl; F Sedlmayer; R Souchon; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2016-03-01       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.